These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

578 related items for PubMed ID: 28978819

  • 1. [Epigenetic dysregulation in myelodysplastic syndromes].
    Sashida G.
    Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
    [Abstract] [Full Text] [Related]

  • 2. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
    Hasegawa N, Oshima M, Sashida G, Matsui H, Koide S, Saraya A, Wang C, Muto T, Takane K, Kaneda A, Shimoda K, Nakaseko C, Yokote K, Iwama A.
    Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
    [Abstract] [Full Text] [Related]

  • 3. [Epigenetic dysregulation in myelodysplastic syndrome].
    Sashida G, Iwama A.
    Rinsho Ketsueki; 2015 Feb; 56(2):111-8. PubMed ID: 25765789
    [Abstract] [Full Text] [Related]

  • 4. [An update on epigenetic regulator gene mutations and pathogenesis of myelodysplastic syndromes].
    Wang JY, Xiao ZJ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1303-9. PubMed ID: 22040993
    [Abstract] [Full Text] [Related]

  • 5. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB, Kadam NN.
    Mutat Res Rev Mutat Res; 2016 Oct; 769():47-62. PubMed ID: 27543316
    [Abstract] [Full Text] [Related]

  • 6. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Cull AH, Mahendru D, Snetsinger B, Good D, Tyryshkin K, Chesney A, Ghorab Z, Reis M, Buckstein R, Wells RA, Rauh MJ.
    Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
    [Abstract] [Full Text] [Related]

  • 7. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.
    Shirahata-Adachi M, Iriyama C, Tomita A, Suzuki Y, Shimada K, Kiyoi H.
    Leuk Res; 2017 Dec; 63():90-97. PubMed ID: 29127861
    [Abstract] [Full Text] [Related]

  • 8. Genetics of myelodysplastic syndromes: new insights.
    Graubert T, Walter MJ.
    Hematology Am Soc Hematol Educ Program; 2011 Dec; 2011():543-9. PubMed ID: 22160087
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients.
    Stomper J, Meier R, Ma T, Pfeifer D, Ihorst G, Blagitko-Dorfs N, Greve G, Zimmer D, Platzbecker U, Hagemeijer A, Schmitt-Graeff I, Lübbert M.
    Clin Epigenetics; 2021 Apr 12; 13(1):77. PubMed ID: 33845873
    [Abstract] [Full Text] [Related]

  • 12. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
    Xu F, Li X, Wu L, Zhang Q, Yang R, Yang Y, Zhang Z, He Q, Chang C.
    Ann Hematol; 2011 Jun 12; 90(6):643-53. PubMed ID: 21125401
    [Abstract] [Full Text] [Related]

  • 13. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, Yang J, Wang CZ, Chai HY, Qian Z, Xiao GF, Xu WR.
    PLoS One; 2011 Jun 12; 6(10):e26906. PubMed ID: 22066015
    [Abstract] [Full Text] [Related]

  • 14. Interpreting new molecular genetics in myelodysplastic syndromes.
    Abdel-Wahab O, Figueroa ME.
    Hematology Am Soc Hematol Educ Program; 2012 Jun 12; 2012():56-64. PubMed ID: 23233561
    [Abstract] [Full Text] [Related]

  • 15. Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2).
    Ma L, Zhang X, Wang Z, Huang L, Meng F, Hu L, Chen Y, Wei J.
    Curr Cancer Drug Targets; 2019 Jun 12; 19(9):729-741. PubMed ID: 30747066
    [Abstract] [Full Text] [Related]

  • 16. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
    Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, Fulton R, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Kandoth C, Baty J, Westervelt P, DiPersio JF, Mardis ER, Wilson RK, Ley TJ, Graubert TA.
    Leukemia; 2011 Jul 12; 25(7):1153-8. PubMed ID: 21415852
    [Abstract] [Full Text] [Related]

  • 17. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
    Larsson CA, Cote G, Quintás-Cardama A.
    Mol Cancer Res; 2013 Aug 12; 11(8):815-27. PubMed ID: 23645565
    [Abstract] [Full Text] [Related]

  • 18. Enhancer DNA methylation in acute myeloid leukemia and myelodysplastic syndromes.
    Benetatos L, Vartholomatos G.
    Cell Mol Life Sci; 2018 Jun 12; 75(11):1999-2009. PubMed ID: 29484447
    [Abstract] [Full Text] [Related]

  • 19. The Impact of Epigenetic Modifications in Myeloid Malignancies.
    Venney D, Mohd-Sarip A, Mills KI.
    Int J Mol Sci; 2021 May 09; 22(9):. PubMed ID: 34065087
    [Abstract] [Full Text] [Related]

  • 20. Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women.
    Wiedmeier JE, Kato C, Zhang Z, Lee H, Dunlap J, Nutt E, Rattray R, McKay S, Eide C, Press R, Mori M, Druker B, Dao KH.
    Exp Hematol; 2016 Sep 09; 44(9):857-865.e5. PubMed ID: 27235757
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.